A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Shuttle Pharma's platform of sensitizers are designed to address the urgent clinical need to improve the outcomes of cancer patients treated with radiation therapy while reducing side effects ROCKVILLE, Md., Aug. 31, 2022 -- Shuttle Pharmaceuticals Holdings, Inc....
ROCKVILLE, Md., Aug. 30, 2022 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...
ROCKVILLE, Md., May 20, 2021 — Shuttle Pharmaceuticals Holdings, Inc., (Shuttle Pharma) a clinical stage company developing drugs to improve the treatment of cancer patients undergoing radiation therapy is pleased to announce the addition of Chris Senanayake,...
ROCKVILLE, Md., Nov. 4, 2020 — Shuttle Pharmaceuticals, Inc (Shuttle Pharma) a clinical stage, Maryland-based, biopharmaceutical company developing new drugs for cancer treatment in combination with radiation therapy, was awarded patent number 10,745,352 by the...